Immunocore Business Model Canvas

Specialized contract manufacturers support complex biologics production and fill-finish for Immunocore, providing scalable capacity, robust quality systems and global GMP compliance. Engaging 2–3 CDMO partners creates redundancy that reduces supply risk and cost volatility. Tech-transfer agreements lock in consistent ImmTAC yields and process control across sites.

Immunocore partners with leading cancer centers and KOLs to drive tebentafusp adoption (OS HR 0.51; 1‑yr OS 73% vs 59%), with FDA/EMA approvals in 2022. CDMO network (2–3 partners) secures GMP supply; companion diagnostics enable HLA-A*02:01 (~40%) patient selection. EHR/data integrations (US EHR adoption 96% in 2024) support enrollment and RWE generation.

Preparation of global submissions, regulatory responses and risk-management plans centers on KIMMTRAK, approved by the FDA in 2022 with a pivotal phase III demonstrating overall survival benefit; ongoing filings target EU and Japan. HEOR programs quantify quality-adjusted life-years and budget impact versus standard of care to support value claims. Pricing, reimbursement and tender negotiations focus on payer demonstrations of survival and cost-effectiveness. Lifecycle management pursues label expansions and combination studies to broaden access.

Discovery/optimization of picomolar TCR‑bispecific ImmTACs; tebentafusp remains sole approved ImmTAC (FDA 2022). IND‑enabling GLP tox, CMC and Phase 1–3 trials (NEJM 2021 pivotal) drive filings and label expansions. GMP scale‑up to 2,000 L bioreactors targets >30% yield gain and 20% COGS cut; 95% on‑time supply and HLA‑A*02:01 ~45% prevalence guide commercial efforts.

Validated, GMP-compliant processes support complex biologics manufacturing, enabling commercial supply of tebentafusp following FDA approval in 2022; scale-up continued through 2024. A network of qualified CDMOs plus internal technical experts manage production and tech transfer. Robust QC/QA systems ensure batch consistency and regulatory release. Dedicated cold-chain and inventory management infrastructure supports global distribution.

ImmTAC IP >200 issued/pending patents (2024) plus trade secrets underpin pipeline and licensing. KIMMTRAK pivotal data: median OS 21.7 vs 16.0 months (HR 0.51); ~73% vs 59% 1‑yr survival, supporting global approvals. GMP-compliant internal processes and qualified CDMO network, QA/QC and cold-chain enable commercial supply and payer/diagnostic partnerships for access.

Immunocore’s scalable platform fuels a repeatable discovery and development engine, supporting over 20 programs across solid tumors and infectious diseases as of 2024, reducing pipeline concentration risk. Modular TCR-based design accelerates candidate selection and optimization, shortening lead cycles. Platform compatibility enables combination regimens to enhance response rates in clinical strategies.

KIMMTRAK, FDA-approved 2022, delivers a phase III OS HR 0.51 in HLA-A*02:01 metastatic uveal melanoma, enabling premium positioning and payer uptake. ImmTAC platform supports >20 programs (2024), precise peptide–HLA targeting, weekly IV dosing, and published 2024 cost-effectiveness evidence supporting reimbursement.

Onboarding includes benefits verification and co-pay assistance with industry programs that can lower therapy abandonment by up to 30% while verifying prior authorization and formulary status for specialty T‑cell therapies. Nurse navigators provide administration and side‑effect education, triage adherence follow‑up and adverse‑event reporting pathways. Support targets adherence amid the WHO estimate of ~50% medication adherence in chronic disease. Multilingual resources address the ~22% of US residents who speak a language other than English at home.

Direct MSL-led clinician engagement, account-based hospital support (72 NCI centers, ~6,000 US hospitals), patient access programs (up to 30% lower abandonment), HLA‑A*02:01 biomarker (~40% EU, ~25% global), nurse navigation, digital CME and 2024 real-world registries/outcomes pilots.

Formulary access via negotiated inclusion with systems and GPOs—about 90% of U.S. hospitals belong to a GPO (2024), enabling broad pathway adoption. Contracts specify structured discounts and supply assurances with committed allocations and turnaround SLAs. Data-sharing agreements deliver real-world evidence and claims integration to support outcomes-based objectives. Contracts align with infusion pharmacy operations for distribution, billing and cold-chain management.

Focused specialty reps target ~99,780 US melanoma cases (2024) and coordinate with MSLs; account KPIs include patient starts, throughput and conversion. Medical affairs runs KOL programs at ASCO/ESMO/SITC and drives tebentafusp evidence post-2022 FDA approval. Digital EHR alerts (HLA-A*02:01 ~40%), tele-detailing (~60% travel reduction) and HLA typing (48–72h) speed identification and initiation.

Commercial insurers, national health services and HTA agencies (eg NICE) demand clear cost-effectiveness evidence, typically judged against thresholds of £20,000–30,000/QALY in the UK and $100,000–150,000/QALY in US assessments, and scrutinize budget impact for therapies often costing >$150,000/yr. They require prespecified use criteria and robust outcomes data and are increasingly willing to consider measurable risk-sharing/outcomes-based agreements.

Core prescribers are medical oncologists at tertiary centers and 72 NCI-designated cancer centers (2024) treating ~2,000–2,500 US uveal melanoma cases/year; patient pool ~5–6/million/year with ~50% metastasis and HLA-A*02:01 prevalence 40–50%. Payers/HTA demand cost-effectiveness (US ~$100k–150k/QALY; UK £20k–30k/QALY) and outcomes-based contracts. Research partners enable pipelines and co-development.

Commercial and medical cost structure centers on a growing sales force and MSL network deployed in 2024 to support KIMMTRAK launches, plus promotional activities and targeted digital campaigns. Ongoing medical education, congress presence and peer‑review publications sustain clinician adoption. Patient support/HUB services and copay assistance increase per-patient service costs. Market access and HEOR programs fund real-world evidence and payer negotiations.

Immunocore cost structure is R&D‑heavy with clinical phases driving ~50–60% of development spend (industry per‑drug ~$1–2.6bn) and CRO/site fees in the tens–hundreds $M for mid/late stages. Manufacturing (CDMO batches $250k–$2M) plus cold‑chain add material/COGS pressure. Commercial, PV, post‑marketing and cybersecurity add recurring multi‑$M OPEX; FY2024 FDA BLA fee ~3.2M USD.

Out-licensing ImmTAC technology or specific candidates to development/commercial partners creates upfront and milestone receipts. Royalty streams arise when partnered programs reach market, e.g., tebentafusp (KIMMTRAK) was FDA approved in 2022 and generates commercial precedent for recurring royalties. Cross-licensing deals secure access to complementary IP and reinforce long-term, high-margin income streams.

Net sales of KIMMTRAK surpassed $300 million in 2024, driven by premium specialty‑oncology pricing and geographic rollouts. Partnership revenues deliver upfronts typically $5–100m and milestone pools that can exceed $1bn for late‑stage oncology. Royalties/profit‑share (often double‑digit) and early‑access programs supplement cash flow; data/HEOR and grants provide small strategic income.